GlassScriptPhysician profile
Priti Manek
NPI 1972551166
$608.28
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2021: $117 · 2022: $334.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $236.22 | 2021-2022 | |
| Gilead Sciences, INC. | $113.28 | 2022 | |
| Mylan Specialty L.P. | $109.19 | 2019 | |
| Novo Nordisk INC | $101.20 | 2022 | |
| Pfizer INC. | $25.91 | 2019 | |
| Melinta Therapeutics, LLC | $22.48 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Manek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.